highlight meet management team includ
management highlight xpovio strong launch far w/ decemb best
month co pleas w/ refil rate day refil indic adher
toler said commonli prescrib dose biw
necessari doc tend dose-reduc mg qw work w/ account
load effect protocol emr better prep ae management comment
see success w/ sale team educ doc w/ symptom management keep
pt tx launch visibl primarili come in-offic dispensari
half xpovio pt get prescript sf present said
reach account gener mm prescript
ask combo mention see subset use off-label combo
w/ combo use frequent -- could bode well add ph iii boston data
support earlier-lin use management highlight us mm pt still get vel dex
mostli commun set ph iii boston posit xpovio
drug approv w/ on-label qw believ provid big market
advantag also svd regimen use less steroid low-dos dex
appeal expect eu approv mm valu
eu realiz boston readout dlbcl addl file expect
eu also highlight new studi w/ xpovio pembro call xport-
expect start ip solid tumor indic start
play year next later boston ph iii top-lin
mm full approv enrol complet siendo endometri sadal dlbcl eu
file condit approv
co highli focus execut ph iii program w/ sparsenten w/ strong
balanc sheet flexibl -- look diversifi pipelin
pursu new indic w/ sparsentan potenti bring new asset co
highlight updat guidanc reach pt enrol
confid base momentum gain reach pt would enabl
report top-lin data primari endpt file acceler
approv add bd continu incred disciplin explor
potenti expand sparsentan new indic show alport preclin data
-- poster show sparsentan may improv hear alport syndrom
could key differenti also look in-licens new asset
thiola ec launch promis w/ pt prior-gen attract new
profil address food intak pill burden feedback physician payer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
posit plan provid updat potenti label expans soon
could provid new revenue project add gener guidanc updat
next ph iii duplex enrol first pt ph iii duplex fsg interim
analysi ph iii protect igan interim analysi potenti launch fsg
co confid strategi estim appeal number pt
ctcl could benefit tx -- indic could allow get across
finish line could potenti expand oppti hl dlbcl pivot
trial ctcl underway w/ readout track -- management happi w/
progress though co comment expect data produc hl
show respons combo w/ could eventu also referenc
doc might use off-label market oppti could get expand even
md blood nk cell trial demonstr proof-of-concept
consid next step cbnk cell tx program includ potenti registr
path anticip also like key part
stori management excit given program could crack open
potenti safer effect option vs cetuximab w/ potenti mutant
tumor like kra much interest w/
remind uniqu epitop target enabl avoid
compet w/ circul igg like featur roch attract along w/
next dose first patient interim efficaci mono
efficaci readout r/r ctcl tmf subtyp mono tx
co sf present show add pozi cohort data note recent
top-lin data w/ tumor reduct waterfal plot look consist w/ pattern
single-sit md data even though respons rate good enough
co said see real biolog activ waterfal plot reflect activ
respect low orr cohort remind trial multi-cent imag done
central potenti respons point mutat exclud --
factor might led lower respons howev variabl known prior
readout investor anticip orr rate decreas md anderson
orr possibl point mutat variabl contribut anticip
anoth key variabl could pt stay suffici drug long enough cross pr
territori believ like explan reconcil waterfal plot
low orr mention sf tox in-lin noth unusu w/ new
side effect said look everyth determin happen
provid find upcom med conf though pozi program could still evolv
concern heel egfr popul
believ enhertu approv lead off-label use base
small compel dataset set complic pozi oppti
mention cohort recruit well rolonti pdufa date
co said start hire mo ahead kept key individu board
prior commerci portfolio believ launch target w/ focu select
corpor account refer exampl small co break
market take share management know sensit cin market look forward
pleas see import disclosur inform page report
compet earlier focus interferon therapeut program said
aggress intern goal recal asset purchas
ucla -- hear next step w/ next
pleas see import disclosur inform page report
inform compani recommend
report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
mauri raycroft ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
mitchel kapoor certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi group llc make market secur adr
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
 within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic
within past twelv month client jefferi llc invest bank servic
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
 one affili within past twelv month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
karyopharm inc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic inc
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
inc one affili
within past twelv month inc client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
inc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic inc
within past twelv month inc client jefferi llc invest bank servic
provid
pleas see import disclosur inform page report
inform compani recommend
report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
